Phase 1/2 Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Phase of Trial: Phase I/II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Gilteritinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 11 Jun 2019 Status changed from not yet recruiting to recruiting.
- 04 Mar 2019 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.
- 04 Mar 2019 Planned primary completion date changed from 1 Feb 2021 to 1 Jan 2021.